Vaccinex (VCNX) Competitors $0.68 +0.02 (+3.09%) As of 03:47 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCNX vs. ACXP, BMRA, BCLI, PHIO, BTAI, NEUP, ADXN, SNSE, PRTG, and AIMDShould you be buying Vaccinex stock or one of its competitors? The main competitors of Vaccinex include Acurx Pharmaceuticals (ACXP), Biomerica (BMRA), Brainstorm Cell Therapeutics (BCLI), Phio Pharmaceuticals (PHIO), BioXcel Therapeutics (BTAI), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Addex Therapeutics (ADXN), Sensei Biotherapeutics (SNSE), Portage Biotech (PRTG), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry. Vaccinex vs. Acurx Pharmaceuticals Biomerica Brainstorm Cell Therapeutics Phio Pharmaceuticals BioXcel Therapeutics Neuphoria Therapeutics Inc. - Common Stock Addex Therapeutics Sensei Biotherapeutics Portage Biotech Ainos Acurx Pharmaceuticals (NASDAQ:ACXP) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Which has preferable earnings and valuation, ACXP or VCNX? Acurx Pharmaceuticals has higher earnings, but lower revenue than Vaccinex. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.58M-$0.70-0.56Vaccinex$388K6.50-$20.25M-$48.27-0.02 Is ACXP or VCNX more profitable? Vaccinex's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -392.36% -223.78% Vaccinex N/A N/A -383.58% Does the MarketBeat Community believe in ACXP or VCNX? Vaccinex received 106 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 94.44% of users gave Acurx Pharmaceuticals an outperform vote while only 60.00% of users gave Vaccinex an outperform vote. CompanyUnderperformOutperformAcurx PharmaceuticalsOutperform Votes1794.44% Underperform Votes15.56%VaccinexOutperform Votes12360.00% Underperform Votes8240.00% Do analysts recommend ACXP or VCNX? Acurx Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 1,951.28%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Vaccinex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in ACXP or VCNX? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 29.6% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to ACXP or VCNX? In the previous week, Acurx Pharmaceuticals had 5 more articles in the media than Vaccinex. MarketBeat recorded 5 mentions for Acurx Pharmaceuticals and 0 mentions for Vaccinex. Acurx Pharmaceuticals' average media sentiment score of 0.55 beat Vaccinex's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acurx Pharmaceuticals Positive Vaccinex Neutral Which has more volatility and risk, ACXP or VCNX? Acurx Pharmaceuticals has a beta of -1.37, meaning that its stock price is 237% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. SummaryAcurx Pharmaceuticals beats Vaccinex on 9 of the 16 factors compared between the two stocks. Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCNX vs. The Competition Export to ExcelMetricVaccinexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.52M$6.47B$5.32B$8.44BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.029.0726.8119.78Price / Sales6.50255.02387.95118.50Price / CashN/A65.8538.2534.62Price / Book-0.376.436.774.52Net Income-$20.25M$143.98M$3.23B$248.32M7 Day Performance-6.73%2.34%1.73%0.58%1 Month Performance29.33%4.47%10.92%13.09%1 Year Performance-82.65%-2.70%17.16%7.74% Vaccinex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCNXVaccinexN/A$0.68+3.1%N/A-87.8%$1.77M$388,000.00-0.0140Gap UpACXPAcurx Pharmaceuticals2.5847 of 5 stars$0.41+4.7%$8.00+1,874.8%-85.3%$9.51MN/A-0.373Analyst RevisionHigh Trading VolumeBMRABiomerica0.1521 of 5 stars$3.60-1.1%N/A-33.3%$9.17M$5.68M-10.5960News CoverageBCLIBrainstorm Cell Therapeutics3.9586 of 5 stars$1.36+3.0%$30.00+2,105.9%-87.3%$8.87MN/A-0.2840Earnings ReportAnalyst ForecastGap UpHigh Trading VolumePHIOPhio Pharmaceuticals2.9373 of 5 stars$1.83-0.5%$4.00+118.6%-73.8%$8.74MN/A-0.1710Positive NewsBTAIBioXcel Therapeutics3.9351 of 5 stars$1.44-0.7%$42.60+2,858.3%-95.7%$8.72M$1.85M-0.0490NEUPNeuphoria Therapeutics Inc. - Common Stock1.546 of 5 stars$4.92flat$21.00+326.8%N/A$8.64M$662,715.000.00N/ANews CoveragePositive NewsEarnings ReportGap UpADXNAddex Therapeutics1.6732 of 5 stars$8.10-0.3%$30.00+270.6%-5.6%$8.58M$556,045.00-23.8130Gap UpSNSESensei Biotherapeutics3.9201 of 5 stars$0.33-4.1%$4.25+1,187.9%-77.1%$8.32MN/A-0.2840PRTGPortage Biotech0.2987 of 5 stars$7.99+1.3%N/A+61.1%$8.28MN/A-0.196Upcoming EarningsGap UpAIMDAinos0.4889 of 5 stars$0.53-2.9%N/A-51.6%$8.15M$20,729.00-0.4140News CoverageGap Down Related Companies and Tools Related Companies ACXP Competitors BMRA Competitors BCLI Competitors PHIO Competitors BTAI Competitors NEUP Competitors ADXN Competitors SNSE Competitors PRTG Competitors AIMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCNX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
